Protalix BioTherapeutics (NYSEAMERICAN:PLX) saw unusually-high trading volume on Friday . Approximately 833,000 shares traded hands during trading, an increase of 13% from the previous session’s volume of 738,542 shares.The stock last traded at $0.45 and had previously closed at $0.43.
PLX has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Protalix BioTherapeutics in a report on Thursday, February 1st. Zacks Investment Research cut Protalix BioTherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 10th.
Protalix BioTherapeutics (NYSEAMERICAN:PLX) last issued its earnings results on Wednesday, May 9th. The company reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.03. The firm had revenue of $4.55 million for the quarter, compared to the consensus estimate of $4.40 million. During the same period last year, the firm earned ($0.48) earnings per share.
Protalix BioTherapeutics Company Profile
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.